(no text — see the shared post below)
8 weeks of Curcumin Supplementation Decreases Liver Fat
This randomised controlled trial involved 87 patients with NAFLD (grades 1-3, diagnosed by liver ultrasound).
Patients were randomised to take curcumin (1000 mg/day in two divided doses) or a placebo for 8 weeks.
Curcumin was provided as a phytosomal formulation that contained a complex of curcumin and soy phosphatidylcholine (Meriva, provided by Indena SpA). Participants in both groups were also given dietary and lifestyle recommendations.
After 8 weeks, curcumin supplementation, but not the placebo, produced statistically significant reductions in body mass index (BMI) and waist circumference (p<.001).
Liver ultrasound findings improved in 75% of subjects in the curcumin group and only 4.7% of subjects in the placebo group.
Improvements on ultrasound were statistically significant in the curcumin group when compared with the placebo (p<.001).
Furthermore, 34.1% of patients in the treatment group saw their liver fat resolve completely, reaching Grade 0. All patients in the treatment group with high-grade (Grade 3) steatosis experienced a reduction in severity.
The effect of curcumin in reducing liver fat remained significant after adjusting for numerous confounding factors. In addition, serum levels of AST and ALT were reduced after 8 weeks of curcumin supplementation but increased in the placebo group. Curcumin was well tolerated, with no reports of serious adverse events.
This study shows that 8 weeks of curcumin supplementation improves sonographic findings and hepatic transaminase levels in patients with NAFLD.
Quoted:
“Supplementation with curcumin was associated with a reduction in body mass index (-0.99±1.25 vs. - 0.15±1.31 in the curcumin and placebo groups, respectively; p=0.003) and waist circumference (-1.74±2.58 vs. -0.23±3.49 in the curcumin and placebo groups, respectively; p=0.024). Ultrasonographic findings were improved in 75.0% of subjects in the curcumin group, while the rate of improvement in the control group was 4.7% (p<0.001). Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p<0.001) but elevated in the control group (p<0.001). Curcumin was safe and well tolerated during the course of trial.”
Paper · Drug Res (Stuttg) · 2017Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.Non-alcoholic fatty liver disease (NAFLD) is a common liver disease characterized by excess lipid deposition in the hepatic tissue and subsequent oxidative and inflammatory damage. Curcumin is a dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties. This study aimed to evaluate the efficacy and safety of supplementation with phytosomal curcumin in subjects with NAFLD.Patients…pubmed.ncbi.nlm.nih.gov
#curcuminHD #liverfatHD #fattyliverHD #liverfatsummaryHD